Clinical Trials

120 enrolled

NSCLC

NCT07340164 2026-01-14

TROY

116 enrolled

Ovarian Neoplasms, Recurrence

NCT04966676 2026-01-08

ATLAS

Phase 2 Terminated

5 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07295132 2025-12-19

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

160 enrolled

Ovarian Cancer Recurrent

NCT04765709 2025-12-16

BRIDGE

Phase 2 Terminated

10 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

112 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07084610 2025-08-22

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06986057 2025-05-22

Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

28 enrolled

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT06234748 2025-05-13

ARTHOUSE

19 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT06908733 2025-04-03

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06775275 2025-01-15

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

60 enrolled

Resectable Lung Non-Small Cell Carcinoma

NCT06614231 2024-09-26

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06313541 2024-06-05

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

146 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06424899 2024-05-22

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

92 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02489006 2024-01-17

NEO

71 enrolled

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04379739 2023-12-06

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

89 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05383001 2022-09-27

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05055583 2021-09-24

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03823625 2020-03-25

SQUINT

112 enrolled

Squamous-Cell Lung Cancer

NCT02845986 2020-02-05

CLASS-04

251 enrolled

Gastrointestinal

Stomach Neoplasms

NCT00391586 2015-08-17

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung

Phase 2 Terminated

45 enrolled 4 charts